Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery

Overview

1. Explore the efficacy of Ulinastatin use in improving post-operative pulmonary insufficiency and safety in pediatric patients undergoing scheduled CPB open heart surgery to treat Complex Congenital Heart Disease 2. Explore the efficacy of Ulinastatin use in improving intraoperative hemodynamic instability as well as other post-operative organ recuperation and its impact on hospital stay & cost

Full Title of Study: “A Randomized, Controlled Trial Evaluating Efficacy of Perioperative Organ Protection as Well as Safety of Ulinastatin Use in Pediatric Patients Undergoing Open Heart Surgery Through CPB to Treat Complex Congenital Heart Diseases”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: June 2018

Detailed Description

Pediatric patients diagnosed with Complex Congenital Heart Disease ready to accept scheduled open-heart surgery under cardiopulmonary bypass (CPB). This study uses randomized (centralized randomization) & controlled design with open label. Eligible subjects will be randomized to receive either study drug (Ulinastatin) or conventional treatment.

Interventions

  • Drug: Ulinastatin
    • Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative

Arms, Groups and Cohorts

  • Experimental: ulinastatin group
    • the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
  • No Intervention: control group
    • patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.

Clinical Trial Outcome Measures

Primary Measures

  • Dynamic changes of arterial oxygen tension / inspired oxygen fraction (PaO2/FiO2) ratio
    • Time Frame: Participants will be followed for the duration of ICU, an expected average of 5 days
    • Dynamic changes of PaO2/FiO2 ratio will be observed in every 4 hours interval during post-operative ICU stay period

Secondary Measures

  • The time of the PaO2/ FiO2 Ratio ≥300 post surgery
    • Time Frame: Participants will be followed for the duration of ICU, an expected average of 5 days
  • The proportion of the PaO2/ FiO2 Ratio ≥300 post surgery
    • Time Frame: Participants will be followed for the duration of ICU, an expected average of 5 days
  • Monitoring arterial hydrogen ion concentration
    • Time Frame: Participants will be followed for the duration of ICU, an expected average of 5 days
  • Monitoring record of mean blood pressure
    • Time Frame: Intraoperative and Postoperative,an expected average of 6 days
  • Monitoring record of central venous pressure
    • Time Frame: Intraoperative and Postoperative,an expected average of 6 days
  • Analysis proinflammatory cytokines Interleukin 1
    • Time Frame: Preoperative and Postoperative on day1 ,day3 and day5

Participating in This Clinical Trial

Inclusion Criteria

1. Children diagnosed with Complex Congenital Heart Disease . 2. Hospitalized children, both gender, aged ≥ 30 days to ≤ 4 years. 3. Preoperative assessment meet with surgical condition. 4. Without signs of Liver, Kidney, and Coagulatory dysfunction. 5. Written informed consent form has been signed by the Legal Guardian. Exclusion Criteria:

1. Patients will accept minimally invasive surgery or palliative surgery, as well as Major Aortopulmonary Collateral Arteries (MAPCAs); 2. Its decided that subject needs to undergo second surgery in a short period of time, or underwent other major surgery. 3. Subjects with known hypersensitivity to study medication (Ulinastatin for Injection) or patients with highly allergic history. 4. Though meeting the study inclusion criteria, the Legal Guardian reject to sign on informed consent. Or at the discretion of study investigator/coinvestigator that the subjects is not appropriate to be included in the study.

Gender Eligibility: All

Minimum Age: 30 Days

Maximum Age: 4 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Techpool Bio-Pharma Co., Ltd.
  • Collaborator
    • Shanghai Children’s Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Wei Wang, MD, Study Chair, Shanghai Children’s Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.